Authorizes physicians and pharmacists to enter into collaborative practice medication adherence protocols for their patients; makes permanent certain provisions relating to authorizing pharmacists to perform with physicians in certain settings.
Summary
Bill A03426, known as the 'Collaborative Practice Medication Adherence Act', aims to amend the public health law and the education law in New York to establish a framework for collaborative practice medication adherence between qualified pharmacists and physicians. This legislation allows pharmacists to engage in collaborative drug therapy management for patients with chronic diseases, ensuring that their medication regimens are appropriate, effective, and safe. The bill seeks to make certain provisions that were previously temporary permanent, thereby enhancing the role of pharmacists in patient care and medication management.
Impact
The enactment of this bill will significantly impact state laws regarding the roles and responsibilities of pharmacists and physicians in managing patient medication adherence. It formalizes the ability of pharmacists to adjust medication regimens under a collaborative practice protocol, which is expected to improve patient outcomes and reduce hospitalizations related to medication mismanagement. This legislation will also require the establishment of protocols that must be reviewed by the state department to ensure compliance with health regulations.
Sentiment
The general sentiment surrounding Bill A03426 appears to be positive, as it aims to enhance patient care through collaborative efforts between pharmacists and physicians. However, there may be concerns regarding the extent of authority granted to pharmacists and the implications for physician oversight. Discussions have highlighted the importance of ensuring that patient safety remains a priority while allowing for more integrated healthcare services.
Contention
Notable points of contention include the scope of authority given to pharmacists in adjusting medication regimens and the potential for conflicts between pharmacists and physicians regarding treatment decisions. Some stakeholders may argue that this could undermine the physician's role in patient care, while others emphasize the need for collaborative approaches to improve medication adherence and patient outcomes. The balance between pharmacist autonomy and physician oversight is a key area of debate.
Same As
Authorizes physicians and pharmacists to enter into collaborative practice medication adherence protocols for their patients; makes permanent certain provisions relating to authorizing pharmacists to perform with physicians in certain settings.
Authorizes physicians and pharmacists to enter into collaborative practice medication adherence protocols for their patients; makes permanent certain provisions relating to authorizing pharmacists to perform with physicians in certain settings.
Authorizes physicians and pharmacists to enter into collaborative practice medication adherence protocols for their patients; makes permanent certain provisions relating to authorizing pharmacists to perform with physicians in certain settings.
Expands the existing law regarding collaborative practice agreements between pharmacists and physicians to allow other healthcare providers to enter into such agreements and removes the definition of “collaborative practice committee.”
Expands the existing law regarding collaborative practice agreements between pharmacists and physicians to allow other healthcare providers to enter into such agreements and removes the definition of “collaborative practice committee.”
Expands the existing law regarding collaborative practice agreements between pharmacists and physicians to allow other healthcare providers to enter into such agreements and removes the definition of “collaborative practice committee.”
Permits licensed pharmacists and nurse practitioners to prescribe and order COVID-19 immunizations; permits physicians to issue non-patient specific orders to pharmacists for COVID-19 immunizations for patients two years of age and older; permits pharmacists to issue patient specific orders for COVID-19 immunizations for patients two years of age and older.